Back to Authors

Mitchell, Stephanie L.

https://orcid.org/0000-0002-1777-7591

Mayo Clinic

University of Pittsburgh

Citations 2

When Should Asymptomatic Persons Be Tested for COVID-19?
Schuetz, Audrey N. , Mehta, Ninad , Campbell, Sheldon , Mitchell, Stephanie L. , Palavecino, Elizabeth , Butler‐Wu, Susan M. , Mehta, Ninad , Mitchell, Stephanie , Butler-Wu, Susan , Schuetz, Audrey N , Hemarajata, Peera , Miller, Melissa B.

Journal of Clinical Microbiology | October 7, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.02563-20 Get It

On 24 August 2020, the Centers for Disease Control and Prevention (CDC) updated its website to highlight that asymptomatic individuals, even those with exposure to a COVID-19-positive contact, do not necessarily need to be tested unless they have medical conditions associated with increased risk of severe illness from COVID-19. The CDC subsequently updated its guidance on 19 September 2020 to support testing of asymptomatic persons, including close contacts of persons with documented SARS-CoV-2 infection.
Application, Verification, and Implementation of SARS-CoV-2 Serologic Assays with Emergency Use Authorization
Theel, Elitza S. , Couturier, Marc Roger , Filkins, Laura , Palavecino, Elizabeth , Mitchell, Stephanie L. , Campbell, Sheldon , Pentella, Michael , Butler‐Wu, Susan M. , Jerke, Kurt, Dharmarha, Vaishali, McNult, Peggy, Mitchell, Stephanie , Butler-Wu, Susan , Schuetz, Audrey N , Schuetz, Audrey N.

Journal of Clinical Microbiology | October 6, 2020 | Volume: 59 | Issue: 1 | Pages: No page available

10.1128/jcm.02148-20 Get It

Interest continues to grow regarding the role of serologic assays for the detection of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) status to many SARS-CoV-2 serologic assays. In this document, expert recommendations from clinical microbiologist members of the American Society for Microbiology (ASM) concerning detailed verification strategies for SARS-CoV-2 serologic assays with FDA EUA are provided, as are insights into assay limitations and reporting considerations for laboratories.